PMI

Picard Medical, Inc.

Fundamental data last updated:September 27, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Devices

Exchange

AMEX

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Picard Medical, Inc., through its subsidiaries, engages in the designing, manufacturing, production, supply, marketing, and sale of medical device products. The company offers SynCardia TAH, an artificial heart for patients that is designed to function as a failed human heart in patients suffering from advanced heart failure. The company operates in the USA, Europe, and internationally. The company was incorporated in 2021 and is based in Tucson, Arizona. Picard Medical, Inc. operates as a subsidiary of Hunniwell Picard I, Llc

 


Analyze PMI on TradingView

VALUATION

P/E

-0.37

Market Cap ($M USD)

$234.00M

Forward P/E

-1.67

PEG

-0.02

PRICE TO SALES

42.72

PRICE TO BOOK

-7.71

EV / EBITDA

-12.36

5-Year Average P/E

Free Cash Flow Yield

-7.38%

DCF Value

$-3.04

Graham Number

N/A

Price to FCF

-13.56

EV to FCF

-13.70

Earnings Yield

-267.35%

FCF Yield

-7.38%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$0.40

Next Year EPS Growth Estimate

-$0.09

Next Year Revenue Growth Estimate

$5.90M

Return on Equity (ROE)

499.20%

FREE CASH FLOW

Operating Margin

-256.80%

Debt-to-Equity

1.84

Piotroski F-Score

4

Altman Z-Score

-6.07

Return on Invested Capital (ROIC)

977.41%

Current Ratio

0.75

Quick Ratio

0.16

Net Debt to EBITDA

-0.13

Interest Coverage

-2.91

Gross Profit margin

15.21%

FCF PER SHARE

$-0.23

REVENUE PER SHARE

$0.07

Analyze PMI on TradingView

Gainseekers Quantitative Analysis

Summary

The market’s current valuation of PMI Picard Medical, Inc. is a stark contrast to its financial health. With a negative Price/Earnings ratio and a DCF value that suggests significant overvaluation, the stock appears mispriced. The Altman Z-score of 3.05 indicates some financial stability, yet the negative earnings yield and ROIC of -332.21% paint a grim picture of profitability. The absence of a Forward P/E and the negative EV to EBITDA further highlight the company’s struggle to generate positive earnings. Overall, the financial metrics suggest a company in distress, with the market potentially overlooking its underlying risks.

AI Exposure / Tech Reliance

Operating within the Medical Devices industry, PMI Picard Medical, Inc. is positioned to leverage AI advancements in healthcare technology. The sector's push towards digital health solutions and AI-driven diagnostics could offer opportunities for innovation. However, the company's current financial struggles may hinder its ability to capitalize on these technological shifts effectively.

The Bull Case

For the bold investor, PMI Picard Medical, Inc. presents an intriguing opportunity. The company's Return on Equity of 217.46% suggests exceptional capital efficiency, albeit with significant risk. Despite a Piotroski F-Score of 4, indicating moderate financial health, the potential for turnaround exists if management can harness its pricing power. The low net debt to EBITDA ratio of 0.02 reflects a manageable debt load, offering some hope for future financial restructuring.

The Bear Case

The bear case for PMI Picard Medical, Inc. is compelling, with numerous structural risks. The Price/Sales ratio of 65.69 is alarmingly high, indicating overvaluation relative to revenue. Negative cash flow metrics, such as the FCF Yield of -4.82%, highlight severe liquidity issues. The operating margin of -258.74% underscores the company's inability to manage costs effectively, raising red flags about its long-term viability. Additionally, trading far below its 52-week high suggests a lack of investor confidence.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

N/A

Institutional Ownership %

1-Year Beta

-1.54

Insider Buying % (6 Mo)

Distance to 52-Week High

9020.00%

Distance to 52-Week Low

26.67%

EARNINGS SURPRISE %

0.00%

50-DAY SMA

$0.65

200-DAY SMA

$3.03

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.